Pepscan acquires stake in Immunovo
Pepscan is to receive a minority stake in Immunovo as part of the companies agreement to partner on development of Pepscan’s therapeutic vaccine portfolio.
Pepscan will also receive an undisclosed cash payment. The firm says partnering its vaccine candidates will allow it to concentrate its resources on the development of mAbs and therapeutic peptides using its protein mimicry technology, CLIPS.
